Akeso, Inc. announced that it entered into a collaboration agreement with Shenzhen Chipscreen Biosciences Co., Ltd., a company listed on the Shanghai Stock Exchange (Stock code: 688321.SH) (Chipscreen Biosciences) to establish a clinical trial partnership to jointly conduct a Phase Ib/II clinical trial of PD-1/CTLA-4 bi-specific antibody Cadonilimab in combination with Chiauranib for the treatment of first-line platinum-based chemotherapy in combination with PD-(L)1 inhibitor treatment regimen for extensive stage small cell lung cancer (ES-SCLC). This cooperation is the specific practice of the Company in the 2.0 era of tumor immunity by adhering to the innovative drug development ideas of openness, diversity and win-win, cooperating with advantageous resources in the industry, deeply exploring the value of products. Leveraging on the advantages of the Chiauranib's dual immunotherapy for oncology and the uniqueness of Chiauranib as a multi-pathway selective kinase inhibitor, the combination therapy is believed to bring more effective clinical benefits to patients in relevant studies of diseases such as lung cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.2 HKD | -4.16% | -4.16% | +1.72% |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+1.72% | 5.47B | |
+7.88% | 115B | |
+12.88% | 107B | |
-13.56% | 22.31B | |
-3.99% | 21.6B | |
-6.59% | 18.23B | |
-39.93% | 17.62B | |
+6.96% | 14.26B | |
+33.17% | 12.37B | |
-28.08% | 8.28B |
- Stock Market
- Equities
- 9926 Stock
- News Akeso, Inc.
- Akeso, Inc. Announces Collaboration with Chipscreen Biosciences to Initiated A Clinical Trial of Pd-1/Ctla-4 Bi-Specific Antibody in Combination with Chiauranib for Pd-(L)1 Pretreated Es-Sclc